



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:
Application No.:

Weenna Bucay-Couto et al.

Date Filed:

10/664,601 09/18/2003

Title:

SOLID OR SEMI-SOLID THERAPEUTIC FORMULATIONS

Group Art Unit.: Confirmation No.:

3626

Atty. Docket No.: 03-278US1

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SIR:

In accordance with 37 C.F.R. §1.56 and in compliance with 37 C.F.R. §\$1.97 and 1.98, the references listed on attached Form PTO/SB/08 and/or subsequently identified herein, are being submitted herewith for consideration by the United States Patent and Trademark Office.

I.	COPIES

a. A legible copy of (i) each foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed, is included herewith.

b. Any patents, publications or other information which are listed on PTO/SB/08 which are not enclosed herewith were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. §120:

U.S. Serial Number

U.S. Filing Date

II. CONCISE EXPLANATION OF THE RELEVANCE (check at least one box)

a. Except as may be indicated below in (b) of this section, all of the patents, publications or other information are in the English language (concise explanation not required).

b. A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:

c. The following additional information is provided for the Examiner's consideration:

III. ☐ CROSS REFERENCE TO RELATED APPLICATION(S)

The Examiner is advised that the following co-pending application(s) contain(s) subject matter that may be related to the present application. By bringing this (these) applications to the Examiner's attention, Applicant(s) does (do) not waive the confidentiality provisions of 35 U.S.C. §122.

Serial No.	Filing Date	Art Unit
60/503,954	9/18/2003	
10/940,589	9/14/2004	1614

The above applications contain subject matter developed by another person, which was disclosed to one or more of the inventors in the present application, before the claimed invention was made.

Docket: 03-278US1

This subject matter and the claimed invention were not, at the time the present invention was made, owned by the same person or subject to an obligation or assignment to the same person.

FEES

IV. 🔯	THIS II	OS IS BEING FILED UNDER 37 C.F.R. §1.97(b): (check one box)
	a. 🔲	within three months of the filing date of a national application other than a continued
		prosecution application under § 1.53(d) (37 C.F.R. §1.97(b)(1)). No fee or statement is
	. —	required.
	b. 🗌	within three months of the date of entry of the national stage as set forth in § 1.491 in an interactional analysis (27.6 F.B. 81.076) (20.00).
	c.🛛	international application (37 C.F.R. §1.97(b)(2)). No fee or statement is required.
		before the mailing date of a first Office Action on the merits (37 C.F.R. §1.97(b)(3)). No fee or statement is required.
	d.	before the mailing date of a first Office Action after the filing of a request for continued examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.
V. 🔲	THIS II	OS IS BEING FILED UNDER 37 C.F.R. §1.97(c): (check one box)
	before t	the mailing date of any of a Final Office Action under 37 C.F.R. §1.113, a Notice of
	Allowar	nce under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the ion (See 37 C.F.R. §1.97(c)).
	a.	No statement; therefore, charge deposit account 50-1047 the fee set forth in 37 C.F.R.
		§1.17(p).
	b. 🗌	See the statement below. No fee is required.
VI. 🔲	THIS IF	OS IS BEING FILED UNDER 37 C.F.R. §1.97(d):
	on or be	fore payment of the issue fee and is accompanied by the following:
	1)	a statement under 37 C.F.R. §1.97(e) as provided below; and
	2)	charge deposit account 50-1047 the petition fee set forth in §1.17(p).
VII. 🔲	STATE	MENT UNDER 37 C.F.R. §1.97(e) (check only one box, if applicable)
	The und	ersigned hereby states that
	a. 🔲	each item of information contained in the IDS was cited in a communication from a
		foreign Patent Office in a counterpart foreign application not more than three months
	. —	prior to the filing of IDS; or
	b. 🗌	no item of information contained in the IDS was cited in a communication from a foreign
		Patent Office in a counterpart foreign application, and to knowledge of the person signing
		the statement after making reasonable inquiry, no item of information contained in the
		IDS was known to any individual designated in 37 C.F.R. 1.56(c) more than three months
	c.	prior to the filing of this statement, or
	¢	some of the items of information contained in the IDS were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each
		item of information contained in the IDS was cited in a communication from a foreign
		Patent Office in a counterpart foreign application not more than three months prior to the
		filing of this IDS. As to the remaining information, the undersigned hereby states that no
		item of this remaining information contained in the IDS was cited in a communication
		from a foreign Patent Office in a counterpart foreign application or, to the knowledge of
		the person signing the statement after making reasonable inquiry, no item of information
		contained in the IDS was known to any individual designated in 37 C.F.R. 1.56(c) more
		than three months prior to the filing of this statement.
VIII.	<u>PAYME</u>	INT OF FEES
		A check in the amount of is enclosed for the above-identified fee(s).
		Please charge Deposit Account No. 50-1047 in the amount of \$180.00 for the above-
		indicated fee(s).

Docket: 03-278US1

It is Applicant(s)' opinion that the claims presently on file patently distinguish the present invention from each of these references. The above references are being cited only in the interests of candor and without any admission that they constitute statutory prior art or contain matter which anticipates the invention or which would render the same obvious, either singly or in a combination, to a person of ordinary skill in the art.
If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 50-1047.
Respectfully submitted,
Keum J. Park MAYER & WILLIAMS Customer Number 27774 Keum J. Park Attorney for Applicant(s) Reg. No. 42,059 Tel.: 908-518-7700
Enclosures: PTO/SB/08 References; US patents/publications omitted, as not required Foreign Search Report Other:
Certificate of Mailing by First Class Mail
I certify that this document and fee is being deposited 12/22/05 with the U.S. Postal Service as first class mail
under 37 C.F.R. 1.8 and is addressed to Mail Stop Amendment, Commissioner
for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Signature of Person Mailing Correspondence
Joanne Ryan Typed or Printed Name of Person Mailing Certificate

Docket No.: 03-278US1

Please type a plus sign (+) inside this box. FORM PTO/SB/85/27 2/ Substitute for form 1449A/PTO Complete if Known **Application Number** 10/664,601 **SUPPLEMENTAL** Filing Date 09/18/2003 INFORMATION DISCLOSURE First Named Inventor Weenna Bucay-Couto **Group Art Unit** STATEMENT BY APPLICANT 1615 Confirmation No. 3626 **Examiner Name** (use as many sheets as necessary) Unassigned of Attorney Docket Number Sheet 2 03-278US1

Examiner Cite	U.S. I	Patent Document	Name of Patentee or	Issue Date	
Initials*	No. 1	Number	Class/Subclass	Applicant of Cited Document	MM-DD-YYYY
<u> </u>	ļ	-			
		<u> </u>			
		+			·

Examiner Cite		U.S. Patent Pub	lication	Name of Patentee or	Date of Publication of Cited Document
Initials*	No.	Number	Class/Subclass	Applicant of Cited Document	MM-DD-YYYY
	1.	20050064046 A1	424/680	DiTrolio	03/24/2005
		(which is a non-provision U.S. Provisional Applie	• •		
				-	

Examiner	Cite		Foreign Patent De	ocument	Name of Patentee or	Date of Publication of Cited Document	T
Initials*	No. 1	Office ³	Number	Class/ Subclass	Applicant of Cited Document	MM-DD-YYYY	
		 					
Examiner					Date		
Signature					Considered	hand shake if asking and	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation, if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3), ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Docket No.: 03-278US1

Substitute f	or form 1449A/PTC)		Con	nplete if Known	
		Application Number	10/664,601			
SUPPLEMENTAL				Filing Date	09/18/2003	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		First Named Inventor	Weenna Bucay-Couto			
		Group Art Unit	1615			
		Confirmation No.	3626			
(use as man	y sheets as necessar	y)		Examiner Name	Unassigned	
Sheet	2	of	2	Attorney Docket Number	03-278US1	

	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
1.	JOSEPH V. DITROLIO, "A Novel Treatment for BPH: Transurethral Ethanol Ablation of the	
	Prostate (TEAP)," slide presentation, 20 th World Congress on Endourology & Shockwave, September 20, 2002, Genoa, Italy, 3 pp.	
,		
		: 3
		Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. 1. JOSEPH V. DITROLIO, "A Novel Treatment for BPH: Transurethral Ethanol Ablation of the Prostate (TEAP)," slide presentation, 20 th World Congress on Endourology & Shockwaye.

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation, if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.